Eton Pharmaceuticals (ETON) Stock Price & Analysis
Score
AI Analysis
SnapshotEton Pharmaceuticals is a growth-led story right now — Growth 94/100 is the pillar doing the heavy lifting (overall 66/100) in Drug Manufacturers - Specialty & Generic. Under the hood: P/E 32.0, plus revenue compounding ~59% annually over recent years. Street targets still imply ~13% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Eton Pharmaceuticals, Inc. (ETON) last printed $63.93. Equity value is $1.84B. Trailing earnings multiple 36.75. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| $0.00 | $0.00 | $959,000.00 | $39,000.00 | $21.83M | $21.25M | $31.64M | $39.01M | $79.95M |
About
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.